注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
和鉑醫藥控股有限公司是一家主要從事腫瘤免疫學及免疫性疾病領域的創新療法開發業務的投資控股公司。該公司的產品包括巴托利單抗,主要用於免疫性血小板減少症、甲狀腺相關性眼病、重症肌無力、視神經脊髓炎譜系疾病等;以及特那西普,主要用於乾眼病。此外,該公司還研究和開發腫瘤免疫產品管線,包括內部開發的新一代腫瘤免疫資產,針對治療免疫沙漠型、免疫排斥型及炎症型腫瘤。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Jingsong Wang | 57 | 2016 | Founder, Chairman & CEO |
Jon Marc Wigginton | - | 2020 | Member of Scientific Advisory Board |
Robert A. Kramer | - | 2016 | Member of Scientific Advisory Board |
Peter F. Moesta | - | - | Member of Scientific Advisory Board & Chief CMC Advisor |
Frank Grosveld | - | 2016 | Member of Scientific Advisory Board |
Yiping Rong | 45 | 2022 | Chief Scientific Officer & Executive Director |
Xiaoping Ye | 59 | 2020 | Independent Non-Executive Director |
Ka Chi Yau | 64 | 2021 | Independent Non-Executive Director |
Robert Irwin Kamen | 79 | 2016 | Independent Non-Executive Director & Member of Scientific Advisory Board |
Zhigang Tian | - | 2020 | Member of Scientific Advisory Board |
Jon Marc Wigginton | 61 | 2020 | Member of Scientific Advisory Board |
Albert R. Collinson | 65 | 2023 | Independent Non-Executive Director |
Weiwei Chen | 57 | 2020 | Senior Business Adviser & Non-Executive Director |
Alexander A. Zukiwski | 66 | 2022 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核